Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels
- PMID: 18383875
Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels
Abstract
Background: Prostate cancer (PCa) is the most common non-skin cancer among men in Western countries. Inflammation appears to be involved in the pathogenesis of PCa. Recent studies have shown that many inflammatory genes are associated with the risk of PCa. Alpha 1 antichymotrypsin (ACT) is an acute phase protein and it is part of the circulating prostate specific antigen (PSA).
Patients and methods: Allele and genotype frequencies of a promoter single nucleotide polymorphism (SNP) in ACT gene were investigated in patients with benign prostate hypertrophy (BHP) or PCa and controls.
Results: The G allele was more represented in PCa patients (odds ratio = 2.349). The PSA levels and prostatic volume did not correlate with the ACT genotype. However, stratifying subjects by age, a correlation of PSA levels and the GG genotype in young PCa patients was found.
Conclusion: Carriers of the ACT G allele are at risk of developing PCa and genotyping healthy subjects could be a new approach for early prevention.
Similar articles
-
A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.Anticancer Res. 2006 Sep-Oct;26(5A):3365-71. Anticancer Res. 2006. PMID: 17094454
-
Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1142-7. doi: 10.1158/1055-9965.EPI-05-0984. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16775173
-
PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.Carcinogenesis. 2007 May;28(5):1032-9. doi: 10.1093/carcin/bgl236. Epub 2006 Dec 6. Carcinogenesis. 2007. PMID: 17151093
-
New circulating biomarkers for prostate cancer.Prostate Cancer Prostatic Dis. 2008;11(2):112-20. doi: 10.1038/sj.pcan.4501026. Epub 2007 Nov 13. Prostate Cancer Prostatic Dis. 2008. PMID: 17998918 Review.
-
Prostate-specific antigen kinetics in localized and advanced prostate cancer.BJU Int. 2009 Mar;103(5):578-87. doi: 10.1111/j.1464-410X.2009.08345.x. Epub 2009 Feb 6. BJU Int. 2009. PMID: 19210674 Review.
Cited by
-
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review.J Inflamm (Lond). 2016 Nov 25;13:35. doi: 10.1186/s12950-016-0143-2. eCollection 2016. J Inflamm (Lond). 2016. PMID: 27924136 Free PMC article. Review.
-
Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.Cancer Gene Ther. 2014 Jan;21(1):2-11. doi: 10.1038/cgt.2013.77. Epub 2014 Jan 10. Cancer Gene Ther. 2014. PMID: 24407349 Review.
-
Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men.Eur Urol. 2014 Oct;66(4):752-68. doi: 10.1016/j.eururo.2014.01.007. Epub 2014 Jan 22. Eur Urol. 2014. PMID: 24491308 Free PMC article.
-
Prostate cancer and inflammation: the evidence.Histopathology. 2012 Jan;60(1):199-215. doi: 10.1111/j.1365-2559.2011.04033.x. Histopathology. 2012. PMID: 22212087 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous